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Abstract
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of venous 
thromboembolism (VTE) resulting from non-dissolving thromboemboli in the pulmonary arteries. 
Previous observations indicate a higher prevalence of atherosclerosis and cardiovascular risk factors in 
patients with VTE and CTEPH. The purpose of the present study was to evaluate the arterial stiffening 
assessed by pulse wave velocity (PWV), a marker of arterial stiffness, in CTEPH patients in comparison 
with a matched control group (CG).
Methods: The study group consisted of 26 CTEPH patients (9 male and 17 female, age 69 ± 10 years) 
and 22 CG (10 male, 12 female, age 67 ± 8 years). In all subjects a physical examination, carotid-
femoral PWV and transthoracic echocardiography were performed. Right heart catheterization was done 
in all CTEPH. 
Results: Chronic tromboembolic pulmonary hypertension patients had significantly higher PWV than CG 
(10.3 ± 2.5 m/s vs. 9 ± 1.3 m/s, p < 0.05), even though systolic blood pressure was higher in CG (120 ± 11 vs. 132 
± 14 mmHg, p = 0.002). PWV correlated only with age and pulmonary vascular resistance (PVR) in CTEPH  
(r = 0.45, p = 0.03 and r = 0.43, p = 0.03, respectively). Arterial stiffening defined as PWV > 10 m/s 
was found in 11 (42%) CTEPH patients and in 5 (23%) cases from CG (p = 0.13). CTEPH patients 
with PWV > 10 m/s were older (74 ± 8 vs. 66 ± 10 years, p < 0.05), had decreased oxygen saturation 
(SaO2 89 [73–96]% vs. 96 [85–98]%, p < 0.01) and tended to have higher PVR (8.1 [3.1–14.0] vs. 5.2 
[3.1–12.7] HRU, p = 0.10).
Conclusions: Arterial stiffness, assessed with PWV, is increased in CTEPH. The elevated PWV is 
associated with older age, lower SaO2 and higher PVR in CTEPH. (Cardiol J XXXX; XX, X: xx–xx)
Key words: arterial stiffness, pulse wave velocity, chronic thromboembolic pulmonary 
hypertension, atherosclerosis
Introduction
Chronic thromboembolic pulmonary hyperten-
sion (CTEPH) is a rare but severe complication of 
pulmonary embolism (PE) caused by the persistent 
obstruction of the pulmonary arteries. CTEPH was 
observed in 3.8% of patients within 2 years after 
acute PE [1].
Recently, the growing number of studies 
suggested that atherosclerosis and venous throm-
boembolism (VTE) can have a common etiology 
involving inflammatory processes [2]. 
“Classic” risk factors for cardiovascular dis-
ease (like smoking, hypertension, diabetes, dyslipi-
demia, and an unhealthy lifestyle) have an impact 
on VTE risk [3]. Patients with symptomatic athero-
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sclerosis were reported to have an increased risk 
of VTE, whereas patients with clinical symptoms 
of VTE more often developed atherosclerosis [2].
The unfavourable structural and functional 
changes in the peripheral arteries caused by ath-
erosclerosis leads to a reduction in their elastic 
properties and finally results in their increased 
stiffness. Aortic stiffening is one of the earliest 
detectable markers of vascular remodeling [4] and 
a predictor of cardiovascular events [5]. The predic-
tive value of aortic stiffening measured as carotid-
femoral pulse wave velocity (PWV) is considered 
the gold standard for assessment of the regional 
arterial stiffening. PWV allows for the prediction 
of cardiovascular mortality regardless of SCORE 
stratification [5, 6].
Risk factors associated with an increase of 
arterial stiffness include age [5, 7], hypertension 
[8] and, to a lesser extent, gender and other clas-
sic risk factors of cardiovascular diseases [5]. A 
recent study has indicated a higher incidence of 
coronary artery disease in patients with CTEPH 
when compared to survivors of acute pulmonary 
embolism with excluded CTEPH [9]. The sug-
gested mechanisms promoting coronary artery 
disease in patients with persistent, non-resolved 
organized pulmonary artery thrombi included in-
flammation, systemic and local hypercoagulability, 
and endothelial injury. All these factors also play an 
integral mechanistic role in the pathophysiology of 
artery stiffening. The aim of the present study was 
to evaluate systemic arterial stiffening assessed 
with PWV in CTEPH patients in comparison with 
a matched control group (CG).
Methods
Patients with CTEPH diagnosis established in 
accordance with European Society of Cardiology/ 
/European Respiratory Society (ESC/ERS) guide-
lines were included in the study [1]. Complet-
ing at least 3 months of effective anticoagulant 
therapy, a mean pulmonary artery pressure 
≥ 25 mmHg, and wedge pressure in the pulmonary 
artery < 15 mmHg in right heart catheterization 
(RHC) present in patients with pulmonary arterial 
perfusion defects on imaging examinations con-
firmed the diagnosis of CTEPH. Patients matched 
by age, gender, and concomitant diseases associ-
ated with atherosclerosis were included in CG. 
Patients with severe diabetes mellitus, chronic 
kidney disease, ischemic heart disease, periph-
eral vascular disease, previous stroke or systemic 
rheumatic diseases were excluded from the study.
A physical examination, carotid-femoral PWV, 
transthoracic echocardiography and six-min-
ute walk test were conducted on the same day, 
while RHC in CTEPH patients performed within 
48 h after PWV. Systemic pulse pressure (PP) 
was calculated as the difference between systolic 
blood pressure (SBP) and diastolic blood pressure 
(DBP).
The study was conducted in accordance with 
the guidelines of Good Clinical Practice and with 
the approval of the local Ethics Committee. All 
patients received detailed information about the 
study and provided  voluntary written consent to 
participate.
Pulse wave velocity assessment
Carotid-femoral PWV measurement was per-
formed after a night’s rest in a horizontal position 
with the camera Complior SR (Artech Medical 
Company, Paris, France) equipped with two TY-306 
tonometric sensors recording changes in pressure 
in the range 0.01–100 Hz, which comprises har-
monic frequencies of pressure waves generated 
at various heart rates. Sensors were placed at the 
right common carotid artery and right femoral 
artery [5]. After the detection, registration, and 
computer processing the impulses were enhanced 
to draw out a curve of the pulse wave of the carotid 
artery and the femoral artery. Then, the time delay 
between the onset of the two pulse waves was 
automatically assessed and the pulse wave veloc-
ity was calculated (the distance between sites of 
measurements, divided by the delay time). The 
mean of three distance measurements was included 
in the analysis. 
The value of the PWV indicating a healthy 
artery is still debatable, however, the ESH/ESC 
2013 guidelines proposed PWV > 10 m/s to be 
considered abnormal [6].
Echocardiography
Transthoracic echocardiography examination 
was performed in all patients according to the 
recommendations of the European Association of 
Cardiovascular Imaging and the guidelines of the 
Echocardiography Working Group of Polish Cardiac 
Society [10, 11]. Phillips iE 33 (Andover, Md., USA) 
with a 2.5–3.5 MHz transducer was used. The size 
of both ventricles, ejection fraction (LVEF) and 
diastolic function of left ventricle, tricuspid annu-
lar plane systolic excursion (TAPSE), pulmonary 
velocity value and pattern, tricuspid regurgitation 
peak gradient, and the dimensions of the inferior 
vena cava were assessed.
www.cardiologyjournal.org 3
Monika Sznajder et al., Increased systemic arterial stiffness in patients with CTEPH
Laboratory tests
Kidney function was estimated according 
to the results of the glomerular filtration rate 
(eGFR) calculated from the Modification of Diet 
in Renal Disease formula from serum creatinine 
concentration.
Six-minute walk test
The distance an individual was able to walk 
over a total of 6 min was measured. Heart rate 
(HR), blood pressure (BP), oxygen saturation 
(SaO2) and dyspnoea (Borg Dyspnoea Score) were 
also recorded before and after exertion [1]. De-
saturation was defined as the difference between 
the baseline arterial blood saturation and SaO2 
measured immediately after the test.
Right heart catheterization
An experienced interventional cardiologist 
performed RHC in patients with CTEPH to confirm 
the diagnosis. The right atrial, right ventricular, 
pulmonary artery and wedge pressures were 
measured. The thermodilution method was used 
to determine stroke volume (SV), cardiac index 
(CI), and indexed pulmonary vascular resistance 
(PVR) [12].
Statistical analysis
Variables with normal distribution are pre-
sented as mean with standard deviation (SD), while 
variables without such distribution are described as 
median and range (min–max). The Student t-test or 
Mann-Whitney test was used for comparisons be-
tween the two groups. The Fisher or c2 tests were 
used to compare discrete variables, as appropriate. 
The Spearman or Pearson correlation coefficients 
were calculated, respectively. A stepforward mul-
tivariable analysis was performed to indicate the 
predictors associated with PWV > 10 m/s. All tests 
were two-sided. Data were considered significant 
at p < 0.05. STATISTICA (StatSoft 13.1, Inc. 2016, 
Tulsa, OK, USA) software was used for statistical 
calculations.
Results
The study group consisted of 26 patients with 
CTEPH (9 men and 17 women, age 69 ± 10 years), 
while 22 patients (10 men, 12 women, age 67 ± 8 
years) were qualified to CG. Patients with CTEPH 
presented II–III World Health Organization (WHO) 
functional class. Dyslipidemia and hypertension 
were present in 8 (30.8%) and 18 (69.2%) patients 
with CTEPH and in 10 (45.5%) and 13 (59.1%) 
of CG, respectively. Total and low-density lipo-
protein (LDL) plasma cholesterol concentrations 
were higher, while high density lipoprotein (HDL) 
cholesterol was lower in CTEPH patients than in 
controls. The prevalence of smoking history and 
diabetes did not differ significantly between groups. 
The clinical characteristics of studied subjects are 
presented in Table 1. CTEPH patients presented 
lower LVEF, decreased TAPSE and increased RV 
to LV dimensions ratio. Moreover, patients with 
CTEPH presented lower GFR than CG. The six-
minute walk distance was remarkably longer in CG 
than in CTEPH patients (Table 1). CTEPH patients 
had significantly higher PWV than controls (PWV 
10.3 ± 2.5 m/s vs. 9 ± 1.3 m/s, p < 0.05) (Fig. 1), 
even though SBP and PP were higher in the control 
group (Table 1). 
Pulse wave velocity correlated only with 
age and PVR in patients with CTEPH (r = 0.45, 
p = 0.03 and r = 0.43, p = 0.03, respectively), while 
in controls PWV correlated with age and inversely 
with body mass index (r = 0.54, p = 0.01 and 
r = –0.43, p < 0.05, respectively). Interestingly, 
there was no correlation between PWV and SBP 
nor DBP in any group. 
There was a borderline correlation between 
PWV and pulmonary compliance (ratio of SV to 
PP) (r = 0.37, p = 0.07), while the association 
between PWV and systemic arterial compliance 
was nonsignificant (r = 0.29, p = 0.16). 
Arterial stiffening defined as PWV > 10 m/s 
was found in 11 (42%) patients with CTEPH and 
in 5 (23%) cases from CG. CTEPH patients with 
PWV > 10 m/s compared to CTEPH patients with 
PWV ≤ 10 m/s were older (74 ± 8 vs. 66 ± 10 years, 
p < 0.05), had decreased oxygen saturation (SaO2 89 
[73–96]% vs. 96 [85–98]%, p < 0.01) and tended to 
have higher PVR (8.1 [3.1–14.0] vs. 5.2 [3.1–12.7] 
HRU, p ≤ 0.10) (Fig. 2). PWV > 10 m/s was not 
associated with lower SaO2 in controls. Multivari-
able analysis revealed the only significant predictor 
of PWV > 10 m/s was SaO2 (odds ratio [OR] 0.90; 
95% confidence interval [CI] 0.68–0.95, p < 0.01).
Discussion
The artery stiffening, associated with increased 
morbidity and mortality, is an important sign of 
systemic vascular disease. PWV is an independent 
predictor of adverse cardiovascular events and all-
cause mortality. A 1 m/s rise of its value increases 
cardiovascular risk by more than 10% [13].
The decreased arterial compliance results in 
an increase of central SBP, limits cardiac output and 
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augments the LV overload. Consequently, coronary 
blood flow is reduced and cardiac ischemia can 
develop [4]. The elevation of the PWV in CTEPH 
patients, compared with the age-matched and 
adjusted for the presence of comorbidity controls, 
indicates an increased arterial stiffness in the 
former. Moreover, the increased arterial stiffness 
in patients with CTEPH may suggest a greater 
risk of developing diseases associated with ath-
erosclerosis. 
Interestingly, the distinct nature of venous 
thrombosis and arterial thrombosis is being fre-
quently questioned in recent studies. There is 
a high number of common risk factors for these 
diseases [2, 3]. Furthermore, patients with clinical 
symptoms of VTE, particularly idiopathic, have an 
increased risk of symptomatic atherosclerosis [2]. 
Additionally, patients with unprovoked VTE have a 
higher risk of acute cardiovascular events including 
acute myocardial infarction and ischemic stroke, 
than patients with provoked VTE [14].
The value of PWV depends on the thickness 
of the vascular wall and its elastic properties. It is 
inversely related to the inner radius of the ves-
sels and blood viscosity. Increased stiffness limits 
systolic expandability, while a loss of flexibility and 
cushioning mechanism leads to an increased SBP 
and a relative reduction of DBP, with a subsequent 
Table 1. Characteristics of the study groups.
Parameters CTEPH (n = 26)  CG (n = 22)  P
Clinical characteristics
Gender (male/female) 9/17 10/12 0.32
Age [years] 69 ± 10 67 ± 8 0.36
BMI [kg/m2] 28 ± 5 29 ± 4 0.23
Heart rate [bpm] 66 ± 11 68 ± 12 0.52
Systolic BP [mmHg] 120 ± 11 132 ± 14 0.002
Diastolic BP [mmHg] 76 ± 11 79 ± 8 0.43
Pulse pressure [mmHg] 43 ± 11 53 ± 12 0.005
eGFR [mL/min] 62 ± 13 89 ± 15 0.0001
SaO2 [%] 91 ± 7 98 ± 1 0.002
6MWD [m] 348 ± 136 599 ± 107 < 0.0001
Total cholesterol [mg/dL] 183 ± 56 144 ± 37 < 0.01
LDL cholesterol [mg/dL] 113 ± 51 79 ± 33 0.01
HDL cholesterol [mg/dL] 55 ± 15 42 ± 14 < 0.01
Triglycerides [mg/dL] 98 ± 46 128 ± 57 0.06
Fasting glucose [mg/dL] 100 ± 39 96 ± 12 0.60
History of smoking 9 (35%) 3 (14%) 0.09
Diabetes mellitus 5 (19%) 1 (5%) 0.15
Echocardiographic parameters
LVEF [%] 55 ± 4 62 ± 4 < 0.0001
TAPSE [mm] 18 ± 5 24 ± 3 < 0.0001
TRPG [mmHg] 74 ± 22 22 ± 10 < 0.0001
RV/LV 1.3 ± 0.3 0.8 ± 0.1 < 0.0001
Right heart catheterization results of CTEPH
mPAP [mmHg] 43 ± 9
PVR [HRU] 6.9 ± 2.9
Cardiac index [L/min/m2] 2.7 ± 0.6
Data are shown as mean ± standard deviation or number (percentage). 6MWD — six minute walk distance; BMI — body mass index; BP — 
blood pressure; CG — control group; CTEPH — chronic thromboembolic pulmonary hypertension; eGFR — glomerular filtration rate; HDL 
— high density lipoprotein; HRU — hybrid reference units (Wood units); LDL — low density lipoprotein; LVEF — left ventricular ejection frac-
tion; mPAP — mean pulmonary artery pressure; PVR — pulmonary vascular resistance; RV/LV — right ventricle/left ventricle; SaO2 — arterial 
oxygen saturation; TAPSE — tricuspid annular plane systolic excursion; TRPG — tricuspid regurgitation peak gradient
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elevation of PP and cardiac afterload [15]. Interest-
ingly, in the current study CTEPH patients were 
found to have higher PWV despite of lower SBP and 
PP. Low SBP is common in CTEPH due to low SV. 
Vascular stiffening develops from a complex 
interaction between stable and dynamic changes 
involving structural and cellular elements of the 
vessel wall, including the role of scaffolding pro-
teins, extracellular matrix, inflammatory mol-
ecules, endothelial cell function, reactive oxidant 
species and genetics [16]. 
In CTEPH the pathological lesions are formed 
by organized thrombi tightly attached to the pul-
monary arterial medial layer, replacing the normal 
intima [17]. The pathophysiology of distal disease 
may involve predominant obstructions of subseg-
mental elastic pulmonary arteries, arteriopathy 
of small muscular arteries and arterioles distal 
to non-obstructed vessels and pulmonary arte-
riopathy of small muscular arteries and arterioles 
distal to totally or partially obstructed vessels 
[18]. Distal pulmonary vasculopathy in both the 
occluded and nonoccluded pulmonary vascular bed 
is characterized by lesions considered typical for 
idiopathic pulmonary arterial hypertension. The 
pathogenesis of these vascular lesions may involve 
the endothelium, platelet production, release of 
mediators and altered pulmonary blood flow. Me-
dial hypertrophy, intimal proliferative, and fibrotic 
changes can be found in CTEPH [19, 20]. However, 
the down regulation of angiogenic gene expression 
and the dysfunction of endothelial cells, which may 
also impair thrombus resolution, were reported as 
well [21]. Moreover, systemic inflammation seems 
to be involved in the development of CTEPH [22]. 
Many patients with CTEPH develop hypox-
emic respiratory insufficiency. In the present study 
PWV correlated with PVR, age and SaO2, however, 
in multivariable analysis decreased SaO2 was the 
only significant predictor of PWV > 10 m/s. The 
association of vascular stiffening with age was 
previously well described [5, 7]. The decreased 
SaO2 can deteriorate endothelium function and in-
crease BP leading to arterial stiffening. Moreover, 
the low oxygen concentration can cause a rise of 
PVR and pulmonary arterial pressure [23]. The 
PVR is related to the geometry of small distal 
resistive pulmonary arterioles and is considered 
to reflect the functional status of pulmonary vas-
cular endothelium/smooth muscle cell coupled 
system. PVR is also positively related to blood 
viscosity and may be influenced by changes in the 
perivascular alveolar and pleural pressure [24]. 
Jujo et al. [20] suggested that a close relationship 
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Figure 1. Pulse wave velocity (PWV) value in control 
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between severe pulmonary arterial remodeling 
and elevated PVR could be the result of luminal 
narrowing of pulmonary muscular arteries. The 
pathomechanisms underlying CTEPH-related 
atherosclerotic arterial alternations are not clear. 
There are no studies available regarding whether 
thromboembolic pulmonary hypertension triggers 
mechanisms that may affect systemic arteries such 
as the aorta. Hou et al. [25] assessed the carotid 
artery in pulmonary hypertension and revealed 
that its stiffening might be related to the release 
of endothelium dependent vasoconstrictors and 
a decreased concentration of vasodilators. Addi-
tionally, in a meta-analysis by Wang et al. [26] which 
included 3198 patients with chronic obstructive 
pulmonary disease, markers of subclinical athero-
sclerosis and cardiovascular risk assessed inter 
alia with PWV were significantly elevated. The 
results of the present study point to a significant 
correlation between arterial stiffening, assessed 
by PWV, and low SaO2, older age, and increased 
PVR. They also suggest an association between 
increased stiffness of the systemic arteries with 
the occlusion of pulmonary arteries and decreased 
blood oxygenation in patients with CTEPH. 
Limitations of the study
This is a single center study on a relatively 
small group of patients with a very rare disease. 
The observations were not blinded, however, due 
to a semi-automatic measurement methodology, 
the influence of the investigator seems negligi-
ble. Based on the results of the current study it is 
impossible to conclude the pathogenesis of arte-
rial stiffening in CTEPH, however, the indicated 
associations suggest possible mechanisms and 
directions for further studies.
Conclusions
Arterial stiffness, a marker of atherosclerosis 
assessed as pulse wave velocity, is increased in 
patients with chronic thromboembolic pulmonary 
hypertension compared to matched controls. The 
elevated PWV is associated with older age, higher 
pulmonary vascular resistance and especially with 
lower oxygen saturation in chronic thromboembolic 
pulmonary hypertension.
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